News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Epigenomics AG Announces Strategic In Vitro Diagnostics Partnership With Abbott Molecular, Inc.


9/26/2007 10:55:07 AM

BERLIN and SEATTLE, Sept. 26, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (ISIN:DE000A0BVT96) has signed today a non-exclusive strategic collaboration and license agreement in molecular diagnostics with Abbott, a global healthcare company. Under the agreement, Abbott and Epigenomics intend to develop an in vitro diagnostic blood test for the early detection of colorectal cancer based on Epigenomics' proprietary DNA methylation biomarker Septin 9.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES